LADENBURG THALM/SH SH reaffirmed their buy rating on shares of SCYNEXIS (NASDAQ:SCYX) in a research report released on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $6.00 target price on the stock.
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of SCYNEXIS from a hold rating to a sell rating in a report on Monday, November 4th. Aegis initiated coverage on shares of SCYNEXIS in a report on Wednesday, July 31st. They issued a buy rating for the company. Needham & Company LLC set a $5.00 target price on shares of SCYNEXIS and gave the stock a buy rating in a report on Friday, October 18th. Brookline Capital Management restated a buy rating on shares of SCYNEXIS in a report on Monday, August 19th. Finally, Maxim Group set a $4.00 target price on shares of SCYNEXIS and gave the stock a buy rating in a report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $4.13.
Shares of NASDAQ SCYX traded down $0.02 during midday trading on Tuesday, reaching $1.17. The stock had a trading volume of 418,200 shares, compared to its average volume of 651,518. The stock has a 50-day moving average of $1.11 and a 200-day moving average of $1.22. The company has a market capitalization of $71.31 million, a price-to-earnings ratio of -2.39 and a beta of 2.36. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.99 and a current ratio of 4.99. SCYNEXIS has a 12-month low of $0.35 and a 12-month high of $1.90.
SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.06 million. SCYNEXIS had a negative net margin of 11,653.81% and a negative return on equity of 141.28%. As a group, analysts forecast that SCYNEXIS will post -0.85 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Creative Planning increased its stake in SCYNEXIS by 11.3% in the 3rd quarter. Creative Planning now owns 154,700 shares of the company’s stock worth $165,000 after buying an additional 15,700 shares during the period. Renaissance Technologies LLC increased its stake in SCYNEXIS by 86.1% in the 2nd quarter. Renaissance Technologies LLC now owns 475,315 shares of the company’s stock worth $623,000 after buying an additional 219,900 shares during the period. BlackRock Inc. increased its stake in SCYNEXIS by 152.0% in the 2nd quarter. BlackRock Inc. now owns 854,880 shares of the company’s stock worth $1,121,000 after buying an additional 515,707 shares during the period. Finally, Vanguard Group Inc. increased its stake in SCYNEXIS by 47.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,373,737 shares of the company’s stock worth $3,110,000 after buying an additional 766,865 shares during the period. 32.82% of the stock is currently owned by institutional investors.
SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
See Also: Back-End Load
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.